Interestingly, low EZH2 levels correlate with poor survival in patients with BRCA2-mutated cancers, suggesting that EZH2 expression levels, similarly to PTIP, can serve as a biomarker for patient response to PARPi therapy (71). Here, BRCA2 is linked to cancer.